Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their disease from worsening for only a few months, with more side effects.
Related posts:
U.S. Task Force Issues Blood Pressure Guidelines
Study finds MDs not always honest with patients
Public hearing set on proposed NY sugary drink ban
After $35 tablet computer, pacemakers may be next
Even Slight Mental Decline Can Harm Health, Studies Suggest
Tot, Virtually Brain Dead, Is Now a Pageant Princess